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Pharmacogenetics, a major component of individualized or precision medicine, relies on human genetic diversity.
The remarkable developments in sequencing technologies have revealed that the number of genetic variants
modulating drug action is much higher than previously thought and that a true personalized prediction of drug
response requires attention to rare mutations (minor allele frequency, MAFo1%) in addition to polymorphisms
(MAF41%) in pharmacogenes. This has major implications for the conceptual development and clinical imple-
mentation of pharmacogenetics. Drugs used in cancer treatment have been major targets of pharmacogenetics
studies, encompassing both germline polymorphisms and somatic variants in the tumor genome. The present
overview, however, has a narrower scope and is focused on germline cancer pharmacogenetics, more specifically,
on drug/gene pairs for which pharmacogenetics-informed prescription guidelines have been published by
the Clinical Pharmacogenetics Implementation Consortium and/or the Dutch Pharmacogenetic Working Group,
namely, thiopurines/TPMT, fluoropyrimidines/UGT1A1, irinotecan/UGT1A1 and tamoxifen/CYP2D6. I begin by
reviewing the general principles of pharmacogenetics-informed prescription, pharmacogenetics testing and
the perceived barriers to the adoption of routine pharmacogenetics testing in clinical practice. Then, I highlight
aspects of the pharmacogenetics testing of the selected drug-gene pairs and finally present pharmacogenetics
data from Brazilian studies pertinent to these drug-gene pairs. I conclude with the notion that pharmacogenetics
testing has the potential to greatly benefit patients by enabling precision medicine applied to drug therapy,
ensuring better efficacy and reducing the risk of adverse effects.
KEYWORDS: Pharmacogenes; Precision Medicine; Thiopurines; Fluoropyrimidines; Irinotecan; Tamoxifen; CYP2D6;
DPYD; TPMT; UGT1A1.
’ INTRODUCTION
Pharmacogenetics (PGx), a major component of individua-
lized or precision medicine, relies on human genetic diversity.
The term pharmacogenetics was coined in 1959 (1) to denote the
study of the influence of genetic factors on the interindividual
variability in drug response. The related term pharmacogeno-
mics first appeared in the 1990s, in the wake of the ‘‘genomic
revolution’’ brought about by genome-wide studies. The terms
are often used interchangeably despite recognition that there are
subtle differences, i.e., the effect of individual genes (pharmaco-
genetics) versus total genomic expression (pharmacogenomics),
and I will use the abbreviation PGx to refer to both. The term
pharmacogene will be applied to denote genes encoding proteins
of importance for pharmacokinetics (drug absorption, distribu-
tion, metabolism and elimination) or pharmacodynamics (drug
effects, whether beneficial or adverse).
As a result of the remarkable developments in next-
generation sequencing technologies, human genomic varia-
tion has been characterized at an unprecedented level of
detail, with major implications for the conceptual develop-
ment and clinical implementation of PGx. It is now evident
that the number of variants with importance for drug action
is much higher than previously thought and that a true
personalized prediction of drug response requires attention
to rare mutations (minor allele frequency, MAFo1%) in
addition to polymorphisms (MAF41%) in pharmacogenes.
Indeed, Kozyra et al. (2) identified a total of 12,152 exonic
single-nucleotide variants in 146 pharmacogenes genotyped
in over 6,600 individuals; most variants were rare (92.9%)
or very rare (MAFo0.1%, 82.7%). These findings were con-
firmed and extended by Schärfe et al. (3), who detected
61,134 variants, predicted to be functional, in 806 pharma-
cogenes from over 60,000 exomes. The vast majority of these
variants (97.5%) had an MAFo0.1%. Collectively, these data
highlight the challenge to PGx implementation in clinical
practice: a substantial effort will be required to catalog these
variants and develop reliable algorithms to identify their
putative functional effects and potential value as drug response
biomarkers.
PGx in oncology
Among medical specialties, oncology has certainly been a
major target for PGx studies and clinical implementation.
This is reflected in the number of publications listed in PubMedDOI: 10.6061/clinics/2018/e565s
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for the combined terms PGx and oncology (Figure 1), in the
proportion of drug labels approved by the United States
Food and Drug Administration (FDA) that contain PGx
information (Figure 2) and in the perception by physicians of
the clinical importance of drug-gene interactions (Figure 3).
While the latter survey covered only germline polymorph-
isms, both germline and somatic variants are represented in
the PubMed data and in the FDA-approved drug labels.
Indeed, the majority of PGx biomarkers in the labels for drugs
used in oncology concern somatic mutations in tumor tissue
(https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm).
In addition to germline and somatic variants affecting phar-
macokinetics or pharmacodynamics, PGx covers yet another
area of interest to oncology, i.e., the activation and detoxifi-
cation of carcinogenic xenobiotics by drug-metabolizing enzymes,
such as CYP1A1, CYP2A6, GSTM1, and GSTT1, which are
encoded by polymorphic genes. A broader scenario of the
PGx of cancer would also comprise pharmacoepigenetics, i.e.,
heritable changes in the function of pharmacogenes that do not
involve changes in the DNA sequence. These various facets of
the PGx of cancer are covered in several excellent, recently
published reviews (4-8). The present overview, however, has a
Figure 1 - PubMed entries for the term ‘‘pharmacogen*’’ (gray columns) or ‘‘pharmacogen AND cancer’’ (https://www.ncbi.nlm.nih.gov/
pubmed/ accessed January 5, 2018).
Figure 2 - Number of FDA-approved labels with PGx information for the therapeutic classes listed on the right. Source: Table of
pharmacogenetic biomarkers in drug labels, https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm, accessed Jan 5, 2018.
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narrower scope and is focused on germline cancer PGx, more
specifically, on drug/gene pairs for which PGx-informed pre-
scription guidelines have been published by the Clinical
Pharmacogenetics Implementation Consortium (CPIC) and/or
the Dutch Pharmacogenetic Working Group (DPWG). These
gene-drug pairs are thiopurines/TPMT, fluoropyrimidines/
UGT1A1, irinotecan/UGT1A1 and tamoxifen/CYP2D6. I begin
by reviewing the general principles of PGx-informed prescrip-
tion, PGx testing and the perceived barriers to the adoption
of routine PGx testing in clinical practice. Then, I highlight
aspects of PGx testing of the selected drug-gene pairs and
finally present PGx data from Brazilian studies pertinent to
these drug-gene pairs.
PGx-informed prescription
The goal of PGx is sometimes presented as providing the
right dose of the right drug for the right patient, ideally at the
onset of treatment. I suggest that a more realistic approach
would be to view PGx as a valuable tool for informing drug
prescription for the individual patient. In some cases, a PGx
test may indeed provide decisive information for or against
the prescription of a given drug. Oncologists are familiar
with companion PGx testing for somatically acquired genetic
variations in tumor tissue to guide the choice of anticancer
drugs (e.g., imatinib, trastuzumab, and cetuximab). How-
ever, there are also germline variants that inform whether a
drug may or may not be prescribed. A distinguished example
is the increased risk of severe, life-threatening dermatological
adverse reactions to carbamazepine in carriers of the HLA-
B*1502 allele. This allele has a very distinct global distribu-
tion (9) with the highest frequency in populations of Asian
descent but is absent or quite rare in African and European
populations. Thus, the FDA recommends that ‘‘patients with
ancestry in at-risk populations should be screened for the
presence of the HLA-B*15:02 allele prior to starting carbamaz-
epine,’’ whereas in Singapore, HLA-B*1502 testing has been
adopted as the standard of care prior to the first use of
carbamazepine (10).
Even when PGx tests are not required or recommended by
regulatory agencies, they may still provide valuable informa-
tion about drug efficacy or toxicity that is ‘‘actionable,’’ i.e.,
may be used to guide PGx-informed prescription. Guidelines
for using actionable PGx information in clinical practice have
been developed by the CPIC (htpps://cpicPGx.org/guide-
lines), the DPWG (https://www.pharmgkb.org/page/dwpg)
and the Canadian Pharmacogenomics Network for Drug Safety
(CPNDS, cpnds.ubc.ca). In total, over 70 dosing guidelines are
currently available that take into account the patient’s genetic
profile (https://www.pharmgkb.org.view/dosing-guidelines.
do). These guidelines rely on genotypic or (occasionally) pheno-
typic information that is already available and do not make
recommendations for when, which or how PGx tests should
be performed. Indeed, the timing and methodology of PGx
tests for germline biomarkers is a matter of debate, specifi-
cally, whether the test(s) should be performed either reactively
for targeted gene(s), with implications for a single drug at
the time it is prescribed, or preemptively using a multigene
panel, which provides genotype information for multiple
pharmacogenes readily available in the patient’s medical
record to inform future drug therapy. Because germline PGx
results have life-long validity, many consider preemptive geno-
typing a panel of PGx markers to be more relevant than
genotyping for individual drug-gene pairs. However, this still
requires systematic investigation.
Implementation of PGx tests
The pros and cons of reactive versus preemptive PGx
testing and the outcomes of PGx implementation using either
approach across a variety of clinical settings were critically
examined in recently published reviews (11,12). One aspect
that I would like to emphasize is that optimization of the
clinical utility of PGx tests, especially preemptive testing,
depends not only on the accuracy of the genotyping proce-
dures but also on the logistics of performing rapid turn-
around genotyping and storing, interpreting, and making the
PGx data readily available to the prescribing physician. The
availability of and access to electronic medical record (EMR)
Figure 3 - Data from a survey among United States physicians on their perception of the clinical relevance of PGx information. The bars
correspond to the percentage of respondents who rated the antineoplastic/gene pairs listed on the right as 1 or 2 (on a scale of 1-5,
where 1 is the most relevant). Source: Relling and Klein (78).
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systems are major factors for the successful implementation
of PGx in clinical practice. Ideally, an EMR system would
provide ‘‘friendly’’ access to the stored PGx information for
authorized prescribing physicians not only from the institu-
tion where the PGx data were generated but also from other
clinical settings where the patient may eventually be treated.
In this regard, the lack of communication among currently
available EMR systems represents a considerable caveat
to the optimal use of preemptive testing. A comprehensive
discussion of EMR PGx integration is available in a recent
article by Caraballo et al. (13), based on their pioneer expe-
rience at the Mayo Clinic.
Other perceived barriers to the clinical implementation of
PGx-informed prescription that require consideration are dis-
cussed below. Further insights into the barriers and solutions
to the implementation of PGx testing may be found in a
recently published review by Klein et al. (14).
Paucity of clear clinical guidelines for translating
genomic variations into actionable
recommendations
The CPIC, DPWG and CPNDS guidelines (see above) con-
tribute decisively to overcoming this barrier, but despite a
high rate of concordance, differences among these guidelines
do exist (15). A related factor is the disagreement among
regulatory agencies with respect to requirement for and per-
ceived clinical utility of PGx. This is illustrated in Table 1,
with information regarding the chemotherapeutic drugs
covered in the CPIC and/or DPWG guidelines, namely, mer-
captopurines, fluoropyrimidines, irinotecan and tamoxifen.
For example, DPWG, but not CPIC, published guidelines for
irinotecan dosing according to UGT1A1 genotype, whereas
among the four regulatory agencies listed in the table, only
Health Canada/Santé Canada (HCSC) requires CYP2D6
genotyping prior to the prescription of tamoxifen for breast
cancer.
Discordance in recommendations for PGx testing extends
to professional societies, a distinct example being fluoro-
pyrimidines for colorectal cancer. Thus, CPIC and DPWG
guidelines provide recommendations for drug prescription
according toDPYD genotype and dihydropyrimidine dehydro-
genase (DPD) activity, while the FDA and the Japanese regu-
latory agency, the PMDA, recognize DPYD information as
actionable. However, the European Society of Medical Oncology
(ESMO) consensus guidelines for the management of patients
with metastatic colorectal cancer state that ‘‘DPD testing (....)
remains an option but is not routinely recommended’’ and
‘‘none of the current strategies are adequate to mandate
routine DPD testing’’ (16). Danesi et al. (17) argued strongly
against these statements and pointed out that they ‘‘do not
reflect the current awareness of the importance of testing
for DPD deficiency y. (and) the Royal Dutch Pharmacists
Association, the French GPCO-Unicancer group and the Italian
Association of Medical Oncology-Italian Society of Pharma-
cology working groups have issued recommendations on
preemptive DPD analysis for rational dose adaptation.’’
Further insights into the disagreements among regulatory
bodies and professional societies regarding PGx may be
found in a review by Gillis et al. (4).
Paucity of prospective randomized clinical trials
(RCTs) validating PGx-guided approaches
So far, prospective RCTs indicating the clinical utility of
PGx tests to guide drug selection have been limited to carba-
mazepine (18), allopurinol (19) and abacavir (20). Nevertheless,
many have argued that the scientific and clinical evidence sup-
porting PGx clinical implementation is substantial for several
other drugs (e.g., warfarin, clopidogrel, simvastatin, trastuzumab,
and cetuximab), despite the lack of prospective RCTs (4,21,22).
Pirmohamed and Hughes (21) proposed that the level of evi-
dence required for the inclusion of PGx tests in treatment
guidelines, drug labeling and reimbursement schemes should
be equivalent to that required for nongenetic diagnostic tests.
Altman (22) argued convincingly that the standard for adopt-
ing PGx-informed prescription should not be superiority to
current practice but rather noninferiority (and the associated
hypothesis of superiority). The validity of this evidence threshold
is supported by the association between TPMT polymorphism
and thiopurine toxicity, which never underwent an RCT and is
yet the most validated and commonly used germline PGx test
in clinical oncology.
Confidence and knowledge of clinicians in
accurately interpreting and acting upon
PGx information
PGx is a relatively novel field, and current evidence points
to a lack of preparedness among practicing clinicians to use
PGx knowledge in routine practice. Indeed, in a survey cover-
ing over 10,000 US physicians, 97.6% agreed that genetic
variations may influence drug response, but only 10.3% felt
adequately informed about PGx testing, and only 29.0%
reported receiving PGx education in either their graduate or
postgraduate training (23). Accordingly, a survey of medical
schools in the United States and Canada in 2010 revealed
that only 28% provided more than 4 hours of instruction
of PGx, and 76% considered that the provision of PGx
Table 1 - Guidelines and label information for germline variants in pharmacogenes associated with antineoplastic drugs.
Drug Gene Guidelinesa Label informationb
CPIC DPWG FDA EMA PMDA HCSC
Azathioprine TPMT + + Testing recommended Actionable PGx Actionable PGx
Mercaptopurine TPMT + + Testing recommended Actionable PGx Actionable PGx
5-Fluorouracil DPYD + + Actionable PGx Actionable PGx
Capecitabine DPYD
Irinotecan UGT1A1 + Dosing information Testing recommended Actionable PGx
Tamoxifen CYP2D6 + + Informative PGx Testing required
aCPIC, Clinical Pharmacogenetics Implementation Consortium (https://cpicPGx.org/guidelines); DPWG, Dutch Pharmacogenetics Working Group (https://
www.pharmgkb.org.page.dpwg).
b Source: PharmGKB website, https://www.pharmgkb.org/view/drug-labels.do. FDA, United States Food and Drug Administration; EMA, European
Medicines Agency; PMDA, Pharmaceutical and Medical Devices Agency (Japan); HCSC, Heal Canada/Sante´ Canada.
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instruction was poor or inadequate (24). Similar results
were reported for British medical schools (25). Furthermore,
PGx instruction, when provided, is included in the initial
semesters of the medical curriculum, rather than later in the
program when the students are more involved in patient
care. PGx implementation, especially in a hospital setting, is
not solely dependent on clinicians but also requires inter-
action with a multidisciplinary team including pharmacists,
nurses and information technologists. Pharmacy schools,
especially in North America, appear to be more active in
implementing PGx education than medical schools (25,26).
Pharmacists have been playing a key role in PGx adoption in
clinical practice in the United States, and some predict that in
the future, pharmacists will play a pivotal role in advising
patients on individualized prescriptions (27).
Cost and reimbursement aspects of PGx testing
As mentioned above, the availability of EMR systems are
critical, if not indispensable, for the optimization of PGx-
informed prescription. Computational tools for clinical deci-
sion support (CDS) will be required to prompt and guide
clinicians to use genetic information when prescribing affected
drugs. With the continuous decline in genotyping prices, the
costs of PGx testing are shifting from laboratory testing toward
the logistics of linking genetic test results to CDS systems that
will robustly guide prescribing and will be routinely updated
as new evidence emerges (28). Nevertheless, the frequency of
PGx variants is a factor to be taken into account: for example,
the combined frequency of the TPMT deleterious alleles
listed in the CPIC guidelines for thiopurines is o5% among
Brazilians (see below). Thus, on average, several hundred
patients need to be genotyped to identify one carrier of two
deleterious alleles who is at a 100% risk of severe myelotoxicity
with conventional doses of mercaptopurine or azathioprine.
PGx testing has been examined is numerous pharmaco-
economic analyses. A PubMed search with the terms ‘‘pharma-
cogen* AND cost-effectiveness’’ (pharmacogen* covers both
pharmacogenetics and pharmacogenomics) yielded 178 review
articles published in 2016 and 2017. The outcomes of
pharmaco-economic analyses are not always concordant,
which is not surprising considering the different methodolo-
gies applied, the country/region where the data were collected
for the analyses, and the perspectives of the payer (e.g., patient,
hospital, health insurance provider, and public health system).
Exploring the reasons for this discordance is beyond the scope
of this article, but I will briefly comment on selected results.
A systematic review of drug-induced adverse effects identi-
fied evidence supporting the cost-effectiveness of testing
for HLA-B*57:01 (prior to abacavir), HLA-B*15:02 and HLA-
A*31:01 (carbamazepine), HLA-B*58:01 (allopurinol), CYP2C19
(clopidogrel) and UGT1A1 (irinotecan); evidence was incon-
clusive for TPMT (thiopurines) (29). Verbelen et al. (30) carried
out a thorough analysis of PGx testing for the biomarkers
listed in the FDA-approved drug labels. Data for pharmaco-
economic evaluation were available for 44 studies of 10 drugs,
of which ‘‘57% drew conclusions in favor of PGx testing...
30% were cost-effective (PGx was more effective at acceptable
additional cost) and 27% were cost-saving/dominant (PGx
was more effective at lower cost).’’
PGx testing in oncology
This section will briefly review the PGx tests for germline
variants associated with cancer chemotherapy drugs, which
have been included in the CPIC and/or DPWG guidelines
and are listed in Table 1. Comprehensive information on the
PGx of each drug/gene pair is available in the CPIC guide-
lines for thiopurines/TPMT, fluoropyrimidines/DPYD and
tamoxifen/CYP2D6 (https://cpicPGx.org/guidelines) and
in recent reviews for irinotecan/UGT1A1 (31,32).
TPMT and thiopurines
Thiopurines (mercaptopurine (MP), thioguanine (TG), and
azathioprine) are widely used anticancer and immunosup-
pressive agents. The three drugs share most pharmacological
effects, but MP and azathioprine are commonly used for
nonmalignant conditions (e.g., inflammatory bowel disease);
additionally, MP is used for lymphoid malignancies, and TG
is used for myeloid leukemias. Thiopurines are prodrugs,
i.e., they must be converted into active thioguanine nucleo-
tide (TGN) metabolites to exert their clinical benefits, as well
as their adverse effects. Thiopurines are also substrates for
other enzymes, which generate inactive metabolites; the
major inactivating pathway is mediated by thiopurine methyl-
transferase (TPMT), encoded by the polymorphic gene TPMT.
The opposing effects of the activating and inactivating enzy-
matic pathways determine the final concentrations of active
TGNs, and, consequently, the magnitude of the effects of
thiopurines. Several variant alleles of TPMT (e.g., *2, *3A, *3B,
and *3C) encode nonfunctional TPMT isoforms, and there is
substantial clinical evidence linking TPMT genotype to the
phenotypic variability of TPMT. Individuals who inherit two
inactive TPMT alleles are at a 100% risk for life-threatening
myelosuppression if they are treated with conventional doses
of thiopurines, whereas those who are heterozygous for non-
functional alleles are at an increased risk, but only B30-60%
appear to be unable to tolerate full doses of MP or azathio-
prine (33).
The CPIC Thiopurine Methyltransferase Genotype and Thio-
purine Dosing Guidelines were first published in 2011 (33),
were updated in 2013 (34) and will be updated again in 2018.
These guidelines provide separate but similar recommenda-
tions for the three thiopurines, according to the individual
TPMT genotype and inferred (or measured) TPMT activity:
for a homozygous wild-type TPMT genotype or normal
TMPT activity, start with the usual dose; for a heterozygous
genotype or intermediate TMPT activity, consider starting
with 30-70% of the target dose; for homozygous variants
or markedly reduced TPMT activity, start with drasti-
cally reduced (10-fold) doses of MP or TG, and consider
alternative agents if using azathioprine. All these recom-
mendations, except for TG in individuals with a hetero-
zygous TPMT genotype, are classified as ‘‘strong,’’ which is
the highest of the three-level rating scale adopted by CPIC
for evidence-based recommendations. For azathioprine in
heterozygous individuals, the recommendation is rated
‘‘moderate.’’
PGx testing for thiopurine/TPMT is routinely performed
in several medical centers abroad for cancer and inflamma-
tory bowel disease (IBD) patients. Relling et al. (35) reported
the use of PGx-guided thiopurine therapy in acute lympho-
blastic leukemia (ALL) since the early 1990s at the St. Jude
Children’s Hospital. A recent survey showed that six sites of
the Translational Pharmacogenomics Program of the National
Institutes of Health have cumulatively performed over 20,000
PGx tests for thiopurines/TPMT, with nearly 2,000 (9.4%)
actionable results (12).
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The results of cost-effectiveness analyses of TPMT PGx
tests are inconsistent. For example, TPMT genotyping prior
to thiopurine treatment in pediatric ALL was found to have
a favorable cost-effectiveness ratio in Europe but not in
the United Kingdom (36-37), whereas systematic analyses
of PGx testing for thiopurines/TPMT revealed either incon-
clusive evidence (29) or cost-savings only when the data
were analyzed assuming genotyping results were available
at no extra cost (30). Nevertheless, it has been argued that
‘‘from an ethical point of view, it is highly questionable
whether leukopenia/pancytopenia should be accepted in
patients where screening for TPMT prior to thiopurine
therapy can definitively identify TPMT deficiency, which
leads in 100% of cases to hematotoxicity under standard
dosage of thiopurines’’ (38). This view must be tempered
with the notion that additional genetic and nongenetic factors
may contribute to the toxicity of thiopurines, especially non-
hematological adverse effects (e.g., pancreatitis and hepato-
toxicity), which are poorly predicted by the TPMT genotypes
for the *2 and *3A-*3C alleles. In addition to rare and/or not
yet identified TPMT variants that may affect TPMT activity,
there is evidence that polymorphisms in genes encoding
other enzymes involved in thiopurine metabolism (e.g., ITPA
and NUDT15) modulate systemic exposure to thiopurines.
Indeed, the emerging role of NUDT15 polymorphisms in thio-
purine disposition and dose-related toxicity in ALL deserves
special attention, particularly in patients of Asian descent (39).
DPYD and fluoropyrimidines
The fluoropyrimidine 5-fluorouracil (5-FU) and its oral
prodrug capecitabine (CAP) are commonly prescribed in the
treatment of colorectal, stomach, breast and head and neck
tumors. 5-FU has a narrow therapeutic index, and depending
on the treatment regimen, up to 35% of patients suffer from
severe, potentially fatal adverse effects, including myelo-
suppression, diarrhea, mucositis, hand-foot syndrome and
neurotoxicity. The clinical implications of DPD deficiency
in patients with severe 5-FU-associated toxicity were first
reported in 2000 (40). DPD, encoded by the polymorphic
gene DPYD, is the rate-limiting enzyme in the inactivation of
5-FU in the human liver; consequently, reduced DPD activity
leads to increased exposure to fluoropyrimidines.
Several variants in DPYD are known; of these, four
associated with reduced DPD activity have been consistently
associated with 5-FU toxicity. These variants are labeled
DYPD*2A,DPYD*13,D949V (c2864A4T) and HapB3 (a haplo-
type of intronic SNPs, in complete linkage disequilibrium
with the rs 7507182; Table 2). The first three variants are rare
(MAFo1%) or very rare (MAFo0.1%), whereas HapB3 is rela-
tively common, ranging in frequency from 4.1-4.8% (http://
phase3browser.1000genomes.org/index.html). A meta-analysis
of data from over 7,000 patients demonstrated that the risk of
5-FU-induced toxicity grade X3 is 1.6- to 4.4-fold greater in
carriers of one or more defective DYPD alleles. The authors con-
cluded that ‘‘upfront screening for these variants (DYPD*2A,
*13, 2864T and HapB3) is recommended to improve the safety
of patients with cancer treated with fluoropyrimidines’’ (41).
Both CPIC and DWPC issued guidelines for the PGx-informed
prescription of 5-FU and/or CAP (Table 2). The recently
updated CPIC guidelines (42) adopted an activity score system
to infer DPD phenotypes according to the genotypes at the
4 polymorphic sites listed above. Based on the inferred DPD
phenotypes, the following recommendations are provided: (1)
in poor DPD metabolizers (carriers of two deleterious DPYD
alleles), avoid 5-FU and CAP; (II) in intermediate DPD meta-
bolizers (carriers of one deleterious allele), reduce starting dose
by 25-50% followed by titration of dose based on toxicity; (III)
in normal DPD metabolizers (carriers of no deleterious alleles),
use label-recommended dosage and administration (43). These
CPIC recommendations were rated ‘‘strong,’’ except that for
heterozygous carriers of reduced function alleles, which was
rated ‘‘moderate.’’
PGx tests for the variants listed in the CPIC guidelines
consistently show high specificity but low sensitivity. For
example, in a retrospective analysis of data from 603 Italian
patients with colorectal cancer treated with 5-FU, both single
and combination analyses of DPYD*2A, *13A and the 2846A4T
SNP genotyping tests showed a specificity of 99-100%, while the
sensitivity ranged from 1-12% (41). Low sensitivity as well as
the low prevalence of DPYD functional variants are perceived
as additional barriers to the adoption of PGx testing to prevent
toxicity to fluoropyrimidines. Supporters of PGx testing argue
that the stratification of patients on the basis of DPYD genotype
may help prevent toxicity and is of the ‘‘utmost importance
within a preventive, prognostic, and personalized approach to
patient care in the oncology setting’’ (43); additionally, on a popu-
lation level, upfront DPYD genotyping may save on costs (44).
As alternatives to DPYD genotyping, several phenotypic
methods have been described to assess, directly or indirectly,
DPD enzymatic activity, but these methods are not included in
the CPIC or DWPG guidelines and are not recommended by
professional associations, such as the ESMO or the American
Society of Clinical Oncology (ASCO).
UGT1A1 and irinotecan
Irinotecan is a topoisomerase-I inhibitor that is widely used
in the treatment of metastatic colorectal cancer in combina-
tion with 5-FU/leucovorin (FOLFIRI) and bevacizumab.
Irinotecan is a prodrug that requires in vivo conversion
into the active metabolite 7-ethyl-10-hydroxycamptothecin
(SN-38) to exert its pharmacological effects. SN-38 is elimi-
nated predominantly by glucuronidation, in a reactionmediated
primarily by UDP-glucuronosyltransferase 1A1 (UGT1A1),
encoded by the UGT1A1 gene. Systemic exposure to SN-38 is
related to the number of TA base repeats in the promoter
region of UGT1A1. The wild-type allele (UGT1A1*1) has six
TA repeats, whereas a common variant allele (UGT1A1*28)
has seven TA repeats. Other rarer variants at this locus are
UGT1A1*36 (five repeats) and UGT1A1*37 (eight repeats).
The gene transcription level is reduced by the seven and eight
TA repeat alleles, and consequently, carriers of these alleles
glucuronidate SN-38 less efficiently than patients with the
wild-type genotype and are exposed to considerably higher
plasma concentrations of SN-38. In patients of Asian descent,
UGT1A1*6, an exonic SNP (c.211G4A, rs4148323), is the most
common variant associated with reduced UGT1A1 metabolic
activity (31,32).
The association between UGT1A1*28 genotype and irino-
tecan toxicity, first reported in 2004 (45), has been the subject
of many studies and several meta-analyses, with conflicting
results. For a comprehensive overview of this topic, which
encompasses the UGT1A1*6 variant, the reader is referred to
a recently published ‘‘umbrella’’ assessment of systematic
reviews and meta-analyses (32); here, I will highlight the
main conclusions of this umbrella analysis. The association of
the UGT1A1*28 and *6 polymorphisms with an increased
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risk of developing irinotecan-induced neutropenia and diar-
rhea was confirmed. The association with neutropenia was
dose-independent, whereas for diarrhea it was restricted to
patients receiving medium- or high-dose irinotecan, but not
low-dose irinotecan (o125-150 mg m-2). The coadministra-
tion of 5-FU was not found to affect the association between
UGT1A1 polymorphisms and neutropenia; for diarrhea, the
analysis was underpowered for firm conclusions. Importantly,
in contrast to irinotecan-induced toxicity, the UGT1A1*28 and
UGT1A1*6 polymorphisms showed no association with the
objective response rate to irinotecan.
Two other aspects of the PGx of irinotecan/UGT1A1 merit
attention: first is the possibility of increasing the dose of
irinotecan above 350 mg m-2 in patients with the wild-type
genotype, UGT1A1*/*1. Thus, Innocenti et al. (46) reported
that the maximum tolerated dose (MTD) of irinotecan was
850 mg, 700 mg and 400 mg in patients with the UGT1A1*/*1,
*1/*28 and *28/*28 genotypes, respectively. Accordingly, the
standard dose of 350 mg m-2 should be reduced byB40% in
patients with the *28/*28 genotype, but results in under-
dosing byB10% and 34% in patients with the 1*/*1 and *1/
*28 genotypes, respectively. Trials exploring the outcome of
irinotecan dose adjustment according to UGT1A1 genotype
are underway. A second point that merits consideration is
the cost-effectiveness of PGx testing (UGT1A1 genotyping)
for irinotecan. This has been examined in several studies, with
ambiguous results (29,30,32). Recently, Roncatto et al. (47)
adopted a novel strategy to address this issue based on the
cost of managing irinotecan-induced toxicity. For Italian colo-
rectal cancer patients, the estimated costs were 6-fold greater
for the UGT1A1*28/*28 genotype (4,886 euros) than the wild-
type genotype UGT1A1*1/*1 (812 euros); for heterozygous
patients with the *1/*28 genotype, the estimated costs were
1,119 euros, still significantly higher than for the wild-type
patients. The authors argued that the differential of toxicity
management cost by UGT1A1 genotype is a step toward
demonstrating the clinical utility of PGx testing.
The DWPG guidelines recommend dosage adjustment
only in patients with the UGT1A1*28/*28 genotype who
are candidates for therapeutic schemes with high-dose
(4250 mgm-2) irinotecan. The recommendation is to reduce
the initial dose by 30%, followed by dose adjustment in
response to neutrophil count. For doses o250 mg, no adjust-
ment is suggested. The CPIC issued no guidelines for the
irinotecan/UGT1A1 pair.
CYP2D6 and tamoxifen
Tamoxifen, a selective estrogen receptor modulator, is used
successfully for long-term adjuvant therapy in breast cancer.
Being a prodrug, tamoxifen must be converted into active
metabolites, primarily 4-hydroxy tamoxifen and 4-hydroxy
N-desmethyltamoxifen (endoxifen), to fully exert its phar-
macological actions. Compared with tamoxifen, endoxifen
has substantially lower steady-state concentrations in blood
but has at least 100-fold higher affinity for the estrogen
receptor. The metabolic pathways for tamoxifen in the human
liver, summarized in Figure 4, comprise several enzymes of
the cytochrome P450 (CYP) family, but CYP2D6 is the rate-
limiting step for the formation of endoxifen.
The CYP2D6 gene is highly polymorphic, with over
80 variants listed in the Human CYP Allele Nomenclature
Database (www.pharmvar.org), many of which affect the
gene product, resulting in wide interindividual differences in
CYP2D6 activity. Four major CYP2D6 metabolic phenotypes
are recognized, namely, ultrarapid (UM), normal (NM), inter-
mediate (IM) and poor (PM), of which UM corresponds to
the highest activity and PM to the lowest. CYP2D6 pheno-
types may be identified using ‘‘phenotypic probes’’ (i.e., drugs
that are selectively metabolized by CYP2D6, such as dextro-
methorphan and metoprolol) or inferred from the CYP2D6
genotypes using an activity scoring system (48). For example,
carriers of two null CYP2D6 alleles (e.g., CYP2D6*4/*5) are
inferred to be PMs, individuals with no defective alleles are
NMs (CYP2D6*1/*1), and those carrying multiple copies of
functional alleles (e.g., CYP2D6*1x4/*2) are EMs.
There is consistent evidence that patients carrying decreased-
or no-function CYP2D6 alleles show lower plasma endoxifen
concentrations than those having the homozygous normal
genotype. Interestingly, doubling the tamoxifen daily dose
(20 to 40 mg) eliminated the differences in endoxifen con-
centration during tamoxifen treatment in IM but not PM
patients (49). These findings support the notion that CYP2D6
phenotype is a strong predictor of endoxifen concentration and
suggest that increasing the tamoxifen dose may be a strategy
to maintain an effective plasma endoxifen concentration in
patients carrying decreased-function or null CYP2D6 alleles
(49,50). However, it is still unclear whether endoxifen (or the
ensemble of active tamoxifen metabolites) concentration is
associated with treatment efficacy. There are several excellent
reviews of this topic, and some are referenced here (50-52).
Two very recent systematic analyses of data from more than
13,000 patients reported ‘‘no clinically important association
between CYP2D6 genotype and breast cancer survival in
tamoxifen-treated women’’ (51) and that the overall effects of
different CYP2D6 phenotypes on breast cancer outcomes are
not clear (52). Accordingly, professional societies, such as the
ASCO or National Comprehensive Cancer Network (NCCN)
do not recommend PGx testing for CYP2D6 prior to tamoxifen
therapy. However, the DPWG has published guidelines with
recommendations to ‘‘...consider aromatase inhibitors for
postmenopausal women’’ and ‘‘avoid the coadministration of
CYP2D6 inhibitors’’ in CYP2D6 PM and IM patients. Recently,
the CPIC has also published guidelines focusing on the role
of CYP2D6 genotype in the adjuvant treatment of estrogen
receptor-positive breast cancer (53). Alternative hormonal
therapy (aromatase inhibitors) is recommended for CYP2D6
PM patients and has been proposed as a possibility to be
considered for IM patients. Standard doses of tamoxifen are
recommended for patients with the NM, IM or UM pheno-
types. The coadministration of CYP2D6 inhibitors is to be
avoided in all except CYP2D6 PM patients. Regarding regu-
latory agencies (Table 2), the FDA included PGx information
on the tamoxifen label but made no recommendations regard-
ing PGx testing, whereas testing is recommended by the
PMDA (Japan) and required by the HCSC (Canada).
PGx in Brazil
The Brazilian population, currently in excess of 210 million
individuals, is highly heterogeneous and admixed, a fact that
has far-reaching consequences for PGx (54-56). Recognition
of this fact prompted the creation of a nation-wide network,
the Rede Nacional de Farmacogenética, or Refargen (57),
which presently comprises 19 research groups distributed
over four geographical regions of Brazil (www.refargen.org.br).
The Refargen website presents data on the frequency of PGx
polymorphisms in the Brazilian population obtained from two
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studies: the first study enrolled 1,034 healthy individuals from
four geographical regions who were genotyped for 44 SNPs
in 16 genes; the second study included 270 healthy subjects
from the Southeast region who were genotyped for over 1,900
polymorphisms in 215 pharmacogenes. All participants in both
Refargen studies were also genotyped with panels of ancestry-
informative markers, which provided data for assessment of
the influence of the individual proportions of Native American
(Amerindian), European and African ancestry on the distribu-
tion of the PGx polymorphisms (56,58,59). Collectively, these
studies reveal the following PGx implications: (I) The distri-
bution of PGx polymorphisms among Brazilians varies across
geographical regions and self-reported ‘‘race/color’’ categories
and is best modeled as continuous functions of individual pro-
portions of European and African ancestry. (II) The differen-
tial frequency of polymorphisms impacts the calculations of
sample sizes required for adequate statistical power in clinical
trials performed in different strata of the Brazilian population.
(III) Extrapolation of PGx data fromwell-defined ethnic groups
to Brazilians is plagued with uncertainty. As a corollary to
these conclusions, PGx studies in Brazilian cohorts should be
encouraged to generate supporting data for the implementa-
tion of PGx-informed prescription in our population.
PGx studies of antineoplastic drugs in Brazilians
This section highlights selected examples of Brazilian
studies related to the PGx of the drug-gene pairs listed in the
CPIC and/or DWPG guidelines for cancer chemotherapy
agents. Table 2 presents data from the Refargen website and
other sources for the frequency, among Brazilians, of the
pharmacogenetic variants listed in these guidelines.
TPMT and thiopurines
To the best of my knowledge, complemented by a PubMed
search using the terms ‘‘Brazil* AND TPMT,’’ PGx testing for
TPMT has not been used routinely to guide thiopurine
therapy in Brazil. However, this search revealed a number of
studies assessing the frequency of TPMT polymorphisms
and the distribution of phenotypes among Brazilians. The
combined frequency of the TPMT*2, *3A and *3C non-
functional alleles was 4.5% in the overall Refargen cohort
Figure 4 -Metabolic routes of tamoxifen leading to the active metabolites endoxifen and 4-hydroxytamoxifen, showing the major CYP
enzyme participating in each step.
Table 2 - Frequency (%) among Brazilians of polymorphisms in pharmacogenes listed in the CPIC and DPWG guidelines for
antineoplastic drugs.
Gene/*allele ID number (variant) Self-reported race/colora Sample Reference
White Brown Black Total
sizeb
TPMT 1034 Refargen website
*2 rs1800462 (c.238G4C) 0.4 1.4 1.4 0.9
*3A rs1800460 + rs1142345 0.9 1.1 1.0 1.0
*3B rs1800460 (c.460G4A) 0 0 0 0
*3C rs1142345 (c.719A4G) 1.7 3.7 1.7 2.6
UGT1A1 268 Santoro et al. (68)
*28 rs8175347 (7 TATA repeats) 35.2
*36 rs8175347 (5 TATA repeats) 1.1
*37 rs8175347 (8 TATA repeats) 0.4
DPYD 270 Refargen website
*2A rs391829 (c.1905+1G4A) 0 0 0 0
*13 rs55886062 (c.1679T4G) 0 0 0 0
CYP2D6 phenotypec Activity Scored 1030 Friedrich et al. (71)
UM 42 1.2-4.6 1.2-4.6 0-4.7
IM 0.5-1 3.4-6.9 0-12.7 8.2-12.9
PM 0 2.3-6.7 0-3.4 1.2-6.2
aAccording to the race/color categories adopted by the Brazilian Census, Brown corresponding to "Pardo."
bNumber of individuals.
cMetabolic phenotypes inferred from the CYP2D6 diplotypes: UM, ultrarapid metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.
dActivity Score, as decribed by Gaedigk et al. (48).
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(n=1034 healthy individuals), with relatively similar distri-
butions in self-reported White, Brown (i.e., Pardo) and Black
subjects (Table 2). These data are consistent with those of
previously published studies in Brazilian healthy subjects
(60,61) and children with ALL (62). Reis et al. (60) quantified
the TPMT enzymatic activity in 306 Brazilians and observed
a trimodal distribution of high (89.9% of individuals), inter-
mediate (9.8%) and low (0.3%) TPMT metabolizer pheno-
types; these proportions are in excellent agreement with the
results of the pivotal study performed by Weinshilboum and
Sladek (63).
Collectively, the available data for Brazilians indicate that
0.3% of the population is at a 100% risk of severe toxicity
when exposed to the standard doses of thiopurines and that
B10% are at an increased risk of toxicity with such doses.
It is likely that these numbers, especially the very low pre-
valence of the homozygous mutant TPMT genotype with
greatly reduced TPMTactivity, contribute to the nonadoption
of PGx testing for thiopurine in Brazil. Nevertheless, it must
be emphasized that preemptive TPMT genotyping is a
relatively simple laboratory procedure, which may identify
patients at a 100% risk of severe, potentially fatal hemato-
logical toxicity.
DPYD and fluoropyrimidines
Of the four variants listed in the CPIC and DPWG guide-
lines, the DPYD*2A and *13 alleles were not detected in the
Refargen cohort of 270 healthy subjects, while the other two
(2646A4T and HapB3) were not investigated in this cohort
(Table 2) However, Cunha-Junior et al. (64) identified three
heterozygous carriers of the deleterious mutations DYPD*2A
(n=1) and 2846A4T (n=2) among 33 gastrointestinal patients
treated with 5-FU. These three patients developed severe,
grade 3-4 toxicity, whereas no deleterious mutations were
detected among patients with grade 0-1 toxicity. This revealed a
100% specificity and 23% specificity for DYPD genotyping
in predicting 5-FU-induced severe toxicity. These values are
in good agreement with those of international studies (see
above). Cunha-Junior et al. (64) also explored the use of
13C-uracyl breath tests to predict 5-FU toxicity and concluded
that it has moderate accuracy in discriminating patients
susceptible to severe 5-FU toxicity versus mild or no toxicity.
Gallarza et al. (65) compared DPYD genotyping versus
phenotypic methods (ratio of uracil (U) to dihydrouracil
(UH2) concentration in plasma and saliva) as predictors of
severe fluoropyrimidine toxicity in 60 patients with gastro-
intestinal tumors. Grade 3-4 toxicity was observed in
21 patients (35%). The deleterious variants investigated, namely,
DPYD*2A and *13 and the SNP Y186C (rs115232898), were
not detected in the study cohort, while the UH2/U metabolic
ratios showed moderate correlations (rs=-0.282 in plasma
and -0.515 in saliva) with toxicity grade. The authors sug-
gested that these ratios, especially in saliva, may be promising
functional metrics for assessing the potential for fluoro-
pyrimidine toxicity.
UGT1A1 and irinotecan
Frequency data for the UGT1A1*28 allele in Brazilians
was first reported by Fertrin et al. (66). Our group (67,68)
extended this analysis to UGT1A1*36 and *37 (Table 2).
Collectively, the two sets of data indicate that the UGT1A1*28
allele is quite common (32-40%) among Brazilians, whereas
the alleles *36 and *37 are rare (0.4-1.1%). A PubMed search
using the terms ‘‘Brazil*, irinotecan, UGT1A1’’ disclosed
no entries in the database. However, an extended search
revealed that Hahn et al. (69) developed and validated an
analytical method for the quantification of irinotecan and its
active metabolite, SN-38, in dried blood samples, which
might prove suitable for clinical use.
CYP2D6 and tamoxifen
Different aspects of the PGx of tamoxifen have been
explored in a number of original studies in Brazilians, and
Vianna-Jorge et al. (70) published a careful overview of the
impact of functional polymorphisms in metabolizing enzymes
on the treatment of breast cancer. I will briefly comment on
selected results from the original studies.
Friedrich et al. (71) reported the distribution of CYP2D6
allele variants, genotypes and inferred metabolic phenotypes
in a cohort of 1,034 healthy Brazilians self-reported as White,
Brown or Black and recruited in four different geographical
regions (North, Northeast, Southeast and South) of Brazil.
The overall data for metabolic phenotypes are summarized
in Table 2. The most frequent phenotype in the entire cohort
was EM (83.5%); PM and UM accounted for 2.5% and 3.7%,
respectively. Similar frequencies for inferred CYP2D6 pheno-
types in breast cancer patients were reported in a series of
articles by Antunes and colleagues (72-75). These authors
also measured the plasma levels of tamoxifen and metabo-
lites and investigated associations between the plasma con-
centrations per se or expressed as concentration ratios, with
CYP2D6 phenotypes inferred from genotypes or obtained
using the phenotypic probe dextromethorphan. Among their
many interesting observations was the conclusion that
‘‘CYP2D6 genotyping and/or phenotyping could not fully
predict endoxifen concentrations’’ in plasma. Antunes et al. (75)
also explored the influence of the CYP3A4*22 defective variant
and CYP3A4 phenotype derived from the (omeprazole)/
(omeprazole sulfone) plasma concentration ratio on tamoxifen
metabolism in breast cancer patients. Their results confirmed
the contribution of CYP3A4 to the bioactivation of tamoxifen
and revealed that this contribution ‘‘becomes increasingly
important in cases of reduced or absent CYP2D6 activity.’’
Two other studies examined the frequency of selected
CYP2D6 alleles on recurrence (76) and disease-free survival (77)
in Brazilian women with breast cancer. Both studies included
relatively small cohorts (n=80 and 58), genotyped limited
numbers of known functional CYP2D6 variants and did not
examine copy number variation, which collectively influenced
the conclusions drawn.
Final considerations
PGx seeks to understand the genetic profile of the indi-
vidual patient to optimize drug therapy, increase efficacy,
prevent/reduce adverse effects and improve cost-effectivness.
Pharmacogeneticists fully realize that the genetic component is
one of several variables that modulate drug response. Thus,
it is intuitive that (I) the larger the relative contribution of genetic
factors to the pharmacological response, the greater will be
the importance of PGx-informed drug prescription and (II) the
more polygenic is a drug response, the more complex will
be the clinical implementation of PGx. Accordingly, PGx has
been most successful when dealing with monogenic or oligo-
genic drug traits; distinct examples are the association of HLA
haplotypes with the toxicity of abacavir and carbamazepine.
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Polymorphisms in single genes are also thought to be key
determinants of the toxicity (thiopurines, 5-FU and irinotecan)
or efficacy (tamoxifen) of the antineoplastic drugs examined in
this review. Nevertheless, the PGx-informed prescription of
these drugs is, to the best of my knowledge, rarely or never
performed in most clinical settings in Brazil. This situation
reflects the discouraging impact of the aforementioned barriers
to the routine clinical implementation of PGx tests. Over-
coming these barriers requires collaborative efforts at several
levels, including (I) the availability of PGx tests at an affordable
cost and in a timely manner; (II) the standardization of PGx
testing and result reporting; (III) educational opportunities to
improve the understanding of which test to order, when to
order tests and how to interpret the results; (IV) access to EMR
systems providing CDS and to guidelines for PGx-informed
prescription; and (V) evidence of clinical utility and cost-
effectiveness applicable to the pertinent clinical setting. PGx
testing has the potential to greatly benefit patients by enabling
precision medicine applied to drug therapy, ensuring better
efficacy and reducing the risk of adverse effects. Refargen, the
Brazilian Pharmacogenetics Network (www.refargen.org.br),
provides a framework for these collaborative efforts and
welcomes professionals and students interested in contributing
to the expansion of PGx investigation and clinical adoption
Brazil.
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